Type i CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells

Journal of Immunology

Volumn 197, Issue 12, 2016, Pages 4829-4837

  Engelberts, Patrick J ^a   Voorhorst, Marleen ^a   Schuurman, Janine ^a   Van Meerten, Tom ^b   Bakker, Joost M ^a   Vink, Tom ^a   Mackus, Wendy J M ^a   Breij, Esther C W ^a   Derer, Stefanie ^c   Valerius, Thomas ^c   Van De Winkel, Jan G J ^a,d   Parren, Paul W H I ^a,e,f   Beurskens, Frank J ^a  

^a GENMAB   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD20 ANTIBODY; COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN RECEPTOR; OFATUMUMAB; TYPE I CD20 ANTIBODY; UNCLASSIFIED DRUG; CD20 ANTIGEN; COMPLEMENT COMPONENT C1; IMMUNOGLOBULIN F(AB) FRAGMENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ACCESSORY CELL; ARTICLE; B CELL LYMPHOMA CELL; CANCER CELL DESTRUCTION; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WALDENSTROEM MACROGLOBULINEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; COMPLEMENT CLASSICAL PATHWAY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LYMPHOMA, B-CELL; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; B-LYMPHOCYTES; CELL LINE, TUMOR; COMPLEMENT C1; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, B-CELL; RECEPTORS, ANTIGEN, B-CELL; RITUXIMAB;

EID: 85001977429     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600811     Document Type: Article

References (34)

1. Cheson, B. D. 2010. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28: 3525-3530.
2. Maloney, D. G., A. J. Grillo-López, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T. M. Liles, B. K. Dallaire, et al. 1997. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
3. Lefebvre, M. L., S. W. Krause, M. Salcedo, and A. Nardin. 2006. Ex vivoactivated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J. Immunother. 29: 388-397.
4. Glennie, M. J., R. R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837.
5. Taylor, R. P., and M. A. Lindorfer. 2008. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20: 444-449.
6. Zhou, X., W. Hu, and X. Qin. 2008. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13: 954-966.
7. Beurskens, F. J., S. R. Ruuls, P. J. Engelberts, T. Vink, W. J. Mackus, J. G. van de Winkel, and P. W. Parren. 2008. Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. Blood 112: 4354-4355.
8. Bologna, L., E. Gotti, M. Manganini, A. Rambaldi, T. Intermesoli, M. Introna, and J. Golay. 2011. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J. Immunol. 186: 3762-3769.
9. Cragg, M. S., S. M. Morgan, H. T. Chan, B. P. Morgan, A. V. Filatov, P. W. Johnson, R. R. French, and M. J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101: 1045-1052.
10. Janas, E., R. Priest, J. I. Wilde, J. H. White, and R. Malhotra. 2005. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. 139: 439-446.
11. Melis, J. P., K. Strumane, S. R. Ruuls, F. J. Beurskens, J. Schuurman, and P. W. Parren. 2015. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol. Immunol. 67(2 Pt A): 117-130.
12. Burton, D. R. 1986. Is IgM-like dislocation a common feature of antibody function? Immunol. Today 7: 165-167.
13. Collins, C., F. W. Tsui, and M. J. Shulman. 2002. Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur. J. Immunol. 32: 1802-1810.
14. Diebolder, C. A., F. J. Beurskens, R. N. de Jong, R. I. Koning, K. Strumane, M. A. Lindorfer, M. Voorhorst, D. Ugurlar, S. Rosati, A. J. Heck, et al. 2014. Complement is activated by IgG hexamers assembled at the cell surface. Science 343: 1260-1263.
15. de Jong, R. N., F. J. Beurskens, S. Verploegen, K. Strumane, M. D. van Kampen, M. Voorhorst, W. Horstman, P. J. Engelberts, S. C. Oostindie, G. Wang, et al. 2016. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 14: e1002344.
16. Pawluczkowycz, A. W., F. J. Beurskens, P. V. Beum, M. A. Lindorfer, J. G. van de Winkel, P. W. Parren, and R. P. Taylor. 2009. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183: 749-758.
17. Peipp, M., J. J. Lammerts van Bueren, T. Schneider-Merck, W. W. Bleeker, M. Dechant, T. Beyer, R. Repp, P. H. van Berkel, T. Vink, J. G. van de Winkel, et al. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399.
18. Teeling, J. L., R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. Parren, C. E. Hack, M. Dechant, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
19. Rösner, T., S. Lohse, M. Peipp, T. Valerius, and S. Derer. 2014. Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop. J. Immunol. 193: 1485-1495.
20. van Meerten, T., R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling. 2006. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12: 4027-4035.
21. de Weers, M., Y. T. Tai, M. S. van der Veer, J. M. Bakker, T. Vink, D. C. Jacobs, L. A. Oomen, M. Peipp, T. Valerius, J. W. Slootstra, et al. 2011. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186: 1840-1848.
22. Takei, K., T. Yamazaki, U. Sawada, H. Ishizuka, and S. Aizawa. 2006. Analysis of changes in CD20, CD55, and CD59 expression on established rituximabresistant B-lymphoma cell lines. Leuk. Res. 30: 625-631.
23. Petersen, B. H., J. A. Graham, and G. F. Brooks. 1976. Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity. J. Clin. Invest. 57: 283-290.
24. Hicks, P. S., L. Saunero-Nava, T. W. Du Clos, and C. Mold. 1992. Serum amyloid P component binds to histones and activates the classical complement pathway. J. Immunol. 149: 3689-3694.
25. Kaplan, M. H., and J. E. Volanakis. 1974. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal Cpolysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J. Immunol. 112: 2135-2147.
26. Wolbink, G. J., M. C. Brouwer, S. Buysmann, I. J. ten Berge, and C. E. Hack. 1996. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J. Immunol. 157: 473-479.
27. Petrie, R. J., and J. P. Deans. 2002. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J. Immunol. 169: 2886-2891.
28. Polyak, M. J., H. Li, N. Shariat, and J. P. Deans. 2008. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J. Biol. Chem. 283: 18545-18552.
29. Holder, M. J., A. Chamba, D. L. Hardie, J. P. Deans, and J. Gordon. 2004. Improved access to CD20 following B cell receptor cross-linking at Burkitt's lymphoma cell surfaces. Leuk. Res. 28: 1197-1202.
30. Walshe, C. A., S. A. Beers, R. R. French, C. H. Chan, P. W. Johnson, G. K. Packham, M. J. Glennie, and M. S. Cragg. 2008. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J. Biol. Chem. 283: 16971-16984.
31. Reth, M. 2001. Oligomeric antigen receptors: a new view on signaling for the selection of lymphocytes. Trends Immunol. 22: 356-360.
32. Maity, P. C., A. Blount, H. Jumaa, O. Ronneberger, B. F. Lillemeier, and M. Reth. 2015. B cell antigen receptors of the IgM and IgD classes are clustered in different protein islands that are altered during B cell activation. Sci. Signal. 8: ra93.
33. Rossbacher, J., and M. J. Shlomchik. 2003. The B cell receptor itself can activate complement to provide the complement receptor 1/2 ligand required to enhance B cell immune responses in vivo. J. Exp. Med. 198: 591-602.
34. Barth, M. J., and M. S. Czuczman. 2013. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncol. 9: 1829-1839.